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creativecommons.org/er’s disease. Early markers of Alzheimer’s disease pathology identifiable before clinical change are
needed for the evaluation of preventative treatments. The retina, an extension of the brain, may pro-
vide a noninvasive imaging site.
Methods: Forty-nine adults with DS and 36 age-matched controls completed retinal nerve fibre layer
(RNFL) assessments using optical coherence tomography. RNFL thickness was analyzed in relation
to cognitive status and age and previously acquired cortical thickness and cerebral amyloid b binding
data in a subgroup.
Results: RNFL thickness was greater in the DS group and did not show age-related thinning. RNFL
correlated positively with cognitive scores and cortical thickness and was reduced in participants with
positive cerebral amyloid b binding.
Discussion: Increased RNFL in adults with DS may represent early Alzheimer’s disease–related
changes. Thinning was present in those with cerebral amyloid b binding, independent of age.
 2019 Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords: Down’s syndrome; Alzheimer’s disease; Dementia; Retina; Optical coherence tomography1. Background
People with Down’s syndrome (DS) have a predispo-
sition for developing early-onset Alzheimer’s disease
(AD) pathology and dementia. Development of senile
plaques composed of b-amyloid (Ab) peptide is observed
in virtually 100% of DS individuals over the age of
40 years [1]. Approximately 50% of individuals progressre no conflict of interests.
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licenses/by-nc-nd/4.0/).to a clinical diagnosis of dementia by their 50s [2], a
figure that continues to rise with increasing age. In addi-
tion to increased burden of Ab, people with DS develop
neurofibrillary tangles and have evidence of brain cell
death.
The retina and optic nerve form part of the central ner-
vous system and are derived from the diencephalon during
early foetal development [3]. In many diseases, including
diabetes mellitus, hypertension, and arthritis, characteristic
signs develop in the retina [4]. This study investigated
whether changes reported in the retinas of typically devel-
oping patients with mild cognitive impairment (MCI) or de-
mentia are also observed in the retinas of adults with DS,
before clinical evidence of dementia.ation. This is an open access article under the CC BY-NC-ND license (http://
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“double-hump” pattern, with the thickest areas being the
inferior and superior quadrants, due to the primary blood
vessels crossing the optic nerve head [5]. Degeneration of
the RNFL, shown as decreased thickness, is a normal part
of ageing [6]; however, studies have shown that in patients
with AD and MCI, there is significantly thinner RNFL
when compared with age-matched healthy controls. The
largest RNFL decrease in dementia is seen in the superior
quadrant [7–9], followed by the inferior quadrant, with the
temporal quadrant being “resistant to fibre loss” [10].
Several studies have investigated the correlation between
cognitive ability (measured using the Mini–Mental State Ex-
amination [MMSE] [11]) and RNFL thickness to test the hy-
pothesis that lower scores would correlate with thinner
RNFL. Results have been inconclusive, and a recent meta-
analysis concluded that there was no consistent evidence
of a correlation [12].
Optical coherence tomography (OCT) is a noninvasive
imaging technology that provides high-resolution cross-
sectional images of the retina allowing for micron precision
segmentation of the intraretinal layers [13]. OCT is a prom-
ising technology particularly in populations with low
compliance, there are relatively few exclusion criteria, as-
sessments are easy to undertake, and it is fast and cost-
effective. Few studies have used OCT in people with DS.
Three studies were identified from current literature, two
in children with DS [14,15], and one in a small number of
adults [16]. All studies showed increased thickness in the
macular compared with controls but did not report on
RNFL thickness.
People with DS have an overproduction of Ab that is
driven by the additional copy of the Ab precursor protein
(APP) gene inherited in triplicate in DS. For this reason,
they provide an unparalleled opportunity to study the impact
of excessive Ab before and during the onset of clinical de-
mentia. In this study, the impact of increased Ab burden
on the structure of the retina is examined and its relationship
to well-documented brain changes explored. Retinal
changes associated with AD may be valuable as proxy
outcome measures in future clinical trials.2. Methods
2.1. Study design and participants
Forty-nine participants with DS and 36 healthy controls
completed OCT imaging and neuropsychological assess-
ments. Participants with DS were identified from a preexist-
ing cohort and with assistance from the DS Association.
Control participants were recruited through the University
and were age-matched to the DS group. Ethical approval
was given by the East of England Cambridge Central
Research Ethics Committee (study ref. 18/EE/1118), and
the study was conducted according to the principles of the
Declaration of Helsinki. Exclusion criteria included recenteye surgery, diabetes mellitus, nystagmus, history of retinal
disease, retinal detachment or previous vitreoretinal proced-
ures, severe cataracts, and presence of psychiatric illness
other than dementia for the DS group and including demen-
tia in the control group. Written informed consent was ob-
tained and for individuals with DS without capacity to
consent a consultee was identified, in accordance with the
Mental Capacity Act, 2005. Previously collected magnetic
resonance and positron emission tomography (MRI and
PET) neuroimaging data on cortical thickness and cortical
Ab binding were available for a subset of the DS group. Neu-
roimaging data were acquired between 2012 and 2014, and
OCT imaging was undertaken between 2015 and 2016.2.2. Procedures
Retinal imaging: Spectral-domain OCT (Heidelberg En-
gineering, Heidelberg, Germany) was used to measure
RNFL thickness using the glaucoma application with auto-
matic retinal tracking enabled. Macular and posterior pole
measures were conducted using the EDTRS (Early Treat-
ment Diabetic Retinopathy Study) grid. Averages were
computed for the fovea, inner macular and outer macular
rings, and for each retinal layer over a 30 ! 25 retinal
area. Image preprocessing was undertaken using the Spec-
tralis Viewing Module (6.3.4.0; Heyex). Automatic segmen-
tation was completed for all images and those with a quality
index ,15 were discarded in accordance with OCT guide-
lines [17]. All measurements for retinal data are given in mi-
crometers (mm). Corresponding retinal measures from both
eyes of each participant were averaged to give a single value.
Before this, paired comparison t-tests were undertaken to
ensure no significant differences between the left and right
eye measurements.
The Cambridge Cognition Examination (CAMCOG-DS)
[18] was used to assess cognitive ability in the DS group.
The CAMCOG-DS, based on the CAMCOG, was specif-
ically designed for people with intellectual disabilities, as-
sessing areas of cognition known to decline with the onset
of dementia. The Cambridge Examination for Mental Disor-
ders in the Elderly for people with DS (CAMDEX-DS)
informant interview [19] was conducted with family mem-
bers and carers of the DS participants. The CAMDEX is a
structured interview of known validity and reliability used
to retrospectively assess changes in an individual’s personal-
ity, behaviour, and functional abilities to determine the pres-
ence or not of dementia and to exclude the possibility of
other disorders that mimic dementia, such as depression
and hypothyroidism.
MRI and PET neuroimaging was completed in a subset of
the DS cohort as part of a previous study. PET scans were ac-
quired in 3D mode on a General Electric Medical Systems
Advanced PET Scanner using Pittsburgh compound [11C]
(PIB). Mean cortical Ab load was calculated in all cortical
regions using the nondisplaceable binding potential
(BPND). Positive PIB binding (PIB 1ve) status was
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ing at least two standard deviations above that of the mean
PIB Ab load in the striatum. Participants that did not meet
this criteria were given a PIB negative (PIB 2ve) status.
MRI scans were completed on a 3-Tesla Siemens Magnetom
Verio Scanner (Siemens, AG, Germany). Cortical thickness
was assessed with FreeSurfer (version 5.3) using the proto-
col devised by Fischl and Dale [20]. Full details on the im-
aging data acquisition and the methodology for PIB group
division are published in Annus et al. (2016) [21].
2.3. Statistical analysis
Statistical analysis was performed using IBM SPSS Sta-
tistics 23. Data were tested for normal distribution and out-
liers. The Bonferroni correction was applied to control for
multiple comparison effects, and the adjusted P value of
0.012 was considered significant throughout unless other-
wise stated. Sample size calculations were determined
from previous research studies in MCI and dementia.
2.4. Role of the funding source
The funders of this study had no role in study design, data
collection, data analysis, data interpretation, or writing of the
paper and submission for publication.3. Results
Sixty participants with DS and 37 typically developing
controls were recruited to this study. Four DS participants
withdrew from the study. Eight participants’ (seven DS
and one control) data were below the acceptable OCT image
quality threshold and removed from analyses. Previously
collected neuroimaging data from an earlier study were
available for 17 DS participants, and these participants
formed a subgroup for analyses relating brain and retinal
changes. Demographics of all groups can be seen in Table 1.Table 1





standard deviation Age range
DS 49 26:23 35.80 6 9.48 18–55
Controls 36 13:23 37.68 6 12.01 21–56
PIB subgroup 17 8:4 42.06 6 7.08 34–55
PIB 1ve group 5 2:3 50 6 5 42–55
PIB 2ve group 12 8:4 38.75 6 4.82 34–47
PIB 1ve matched
control group
8 2:6 53.5 6 2.07 50–55
PIB 2ve matched
control group
12 4:8 38.2 6 5.03 31–46
NOTE. Subgroups include participants with DS who underwent prior
neuroimaging and amyloid binding group based on PIB binding potential
identified. Control participant subgroups are age matched to DS PIB
groups.
Abbreviations: DS, Down’s syndrome; PIB, Pittsburgh compound
[11C].There were no significant age or sex differences between
DS and healthy control groups (age: t(64.530) 5 2.815,
P 5 .435; sex: c(1) 5 2.401, P 5 .121). Within the DS sub-
group, participants with PIB1ve binding status were signif-
icantly older than those in the PIB 2ve group
(t(15)524.337, P5 .001). For subgroup analyses, typically
developing participants were matched to each of the binding
status groups for comparison. There were no significant dif-
ferences in age between these groups (PIB1ve and matched
controls: t(11) 5 .120, P 5 .228; PIB 2ve and matched con-
trols: t(22) 5 .248, P 5 .806).3.1. Comparisons between RNFL thickness in DS and age-
matched controls
Contrary to the hypothesis, results showed increased
thickness in global RNFL (P , .001), and RNFL quadrants
(P , .001), in the DS group when compared with age-
matched controls with the exception of the nasal quadrant
(P 5 .378). The largest difference between groups was
seen in the inferior quadrant with the DS group having an
average of 27.6 mm thicker than the control group. Superior
and temporal quadrants also had average differences of
.20 mm thicker in the DS group.
Other than increased thickness, the structure of the
retina was not strikingly different in the DS group. In
both groups, thinnest RNFL was observed in the nasal
and temporal quadrants, and the thickest RNFL was seen
in the inferior and superior quadrants. In the control group,
there were no significant differences between nasal and
temporal quadrants, or between inferior and superior quad-
rants; however, in the DS group, there were significant dif-
ferences between all quadrants (P , .001). Average
thickness values of both groups are shown in Fig. 1. Exam-
ples of the RNFL images and differences between age- and
sex-matched DS and control participants are shown in
Supplementary Material.3.2. Additional OCT parameters
The primary focus of this article is to discuss thickness
and structural differences in the RNFL with respect to
age and onset of AD. Owing to unexpected findings of
thicker RNFL in adults with DS, we also explored the pa-
rameters of the macular and posterior pole, to support the
findings in the RNFL and to further explore retinal
differences.
The macular was significantly thicker in the DS group
(n 5 39) compared with the matched controls (n 5 36) in
both the fovea t(73)5 4.379, P, .001, and the outer macular
t(73)5 5.137, P, .001. The inner macular was thicker by an
average of 9 mm in the DS group, but this was not signifi-
cantly different (P 5 .020).
Furthermore, comparisons of the posterior pole were con-
ducted between the groups, DS participants had significantly
thicker inner retinal layers, t(73)5 4.480, P, .001; however,
Fig. 1. Grouped bar chart showing the mean RNFL thickness (mm) across the DS and age-matched healthy control groups. Global RNFLT and RNFLT of all
quadrants except the nasal were significantly thicker in the DS group. **P , .001. Abbreviations: DS, Down’s syndrome; NS, not significant; RNFL, retinal
nerve fiber layer.
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t(73) 5 22.889, P 5 .005.
Further exploration of the retinal layers was under-
taken, finding no significant differences between the
RNFL and the retinal pigment epithelium layers and,
additionally, the outer nuclear layer was significantly
thinner in the DS group. This layer appears to be driving
the significant difference in the outer layers between
groups, as the outer plexiform layer was significantly
thicker in the DS group along with the majority of other
layers. Thinner outer nuclear layer is an intriguing finding
that is not supported by previous DS studies in children,
and the outer nuclear layer has been shown to decrease
in thickness in those with AD compared with controls
[22], though relatively few studies have considered the
posterior pole layers in retinal analysis. Table 2 showsTable 2
Macular and posterior pole measures between DS and age-matched controls
Retinal area DS (n 5 39) Controls (n 5 36) P
Fovea 299.65 1 28.80 274.18.80 ,.001
Inner macular 355.56 1 19.17 346.42 1 13.80 .021
Outer macular 320.83 1 14.75 303.93 1 13.64 ,.001
Inner layers average 236.64 2 13.47 221.80 1 12.00 ,.001
RNFL 41.27 1 6.26 41.32 1 4.22 .963
Ganglion cell layer 41.13 1 3.42 33.35 1 2.27 ,.001
Inner plexiform layer 34.67 1 2.52 27.62 1 1.98 ,.001
Inner nuclear layer 40.70 1 32.07 32.07 1 2.42 ,.001
Outer layers average 77.26 1 1.42 78.41 1 1.98 .005
Outer plexiform layer 28.18 1 3.04 26.10 1 1.90 ,.001
Outer nuclear layer 50.77 1 5.82 60.28 1 7.64 ,.001
Retinal pigment epithelium 13.24 1 .99 12.92 1 .87 .142
NOTE. DS sample is lower due to reduced compliance with the retinal
box scan, and there were no significant differences in age between the
reduced DS group and controls (t(65.64) 5 2.609, P 5 .545). The majority
of retinal areas show significantly increased thickness in the DS group. Sig-
nificant P value of P , .012.
Abbreviations: DS, Down’s syndrome; RNFL, retinal nerve fiber layer.additional macular and posterior pole differences between
groups.3.3. Age-related changes in RNFL thickness
In line with evidence from control populations and pa-
tients with AD, it was hypothesized that there would be
increased retinal thinning with age in DS, compared
with controls. Findings showed that there were no correla-
tions between RNFL and age in adults with DS and that
typical patterns of age-related decline were not observed.
RNFL correlations with age ranged between r 5 2.048
and r 5 .102, none of which were significant. For the con-
trols, medium negative correlations of r 5 2.322 and
r 5 2.305 were observed in the global and inferior quad-
rants, respectively. These correlations were not significant
but were supportive of expected age-related thinning
particularly in this population where the maximum age
was 56 years. Scatterplots for both groups are shown in
Fig. 2.
Further analysis was undertaken to assess RNFL differ-
ences across age decades. A scatterplot of the temporal
quadrant values (Fig. 3) shows that there were nonsignifi-
cantly higher RNFL values in DS participants in their 40s
(f(3) 5 3.064, P 5 .221). The average thickness of the tem-
poral quadrant in DS in their 40s was 13 mm higher than
in the 30s and 8 mm higher than in the 20s and 50s. This
was contrary to our predictions that highest RNFL would
be seen in younger participants and would decrease
gradually with age and more dramatically than in control
participants.3.4. Relationship between CAMCOG scores and RNFL
thickness
There was a positive nonsignificant correlation between
CAMCOG scores and superior (r5 .269, P5 .071) and nasal
quadrant thickness (r5 .244,P5 .135) in the DS group. In the
Fig. 2. Cross-sectional age profile of global RNFL in DS and age-matched controls. A nonsignificant age-related decline was seen in the control group as ex-
pected; however, the DS group showed no correlation between RNFL and age. Thickest RNFL measures are seen in the DS group in their 40s. Abbreviations:
DS, Down’s syndrome; RNFL, retinal nerve fiber layer.
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P5 .264) and no correlation in the inferior quadrant.3.5. Exploratory investigations of retinal and cortical
thickness in the presence of cerebral Ab
The link between the brain and the retina and how AD
processes affect both was investigated in the subgroup of
people with DS who had completed both neuroimaging
and retinal studies. Exploratory analyses were undertaken
to explore the relationship between RNFL and cortical thick-
nesses and whether retinal structure differs in those who had
previously been identified as having positive cerebral Ab
binding.
The small number of participants in this subgroup had un-
dergone MRI and PET neuroimaging between one and four
years before retinal imaging. It was predicted that those with
a historic status of positive Ab binding would have thinner
retina than those with a negative binding status at that
time. It was hypothesized that there would be a strong
positive correlation between retinal thickness and corticalFig. 3. Grouped plot showing inferior quadrant RNFL of PIB groups and matched
ferences were only seen between the PIB2ve and matched groups. No significant d
group. *P , .012. Abbreviations: DS, Down’s syndrome; NS, not significant; RNthickness and that both retina and cortex would be thinner
in those with positive Ab cerebral binding.
Comparisons between the PIB 1ve and PIB 2ve groups
showed that there were no significant differences in RNFL
thickness. It was noted, however, that the PIB1ve group dis-
played lower thickness in all but the temporal quadrant.
Further investigations compared the retinal thicknesses of
each PIB group with an age-matched control group. As
with the full DS group, the PIB2ve group had significantly
thicker RNFL in every quadrant except nasal; however, in
the PIB 1ve group, the superior and inferior quadrants
were statistically similar to the control group. This result
suggests that there is reduced RNFL thickness in DS who
are PIB 1ve positive, lowering the values to those seen in
typically developing controls. Temporal quadrant thickness
in both PIB groups and their matched control groups are
shown in Fig. 3.
Cortical thickness was compared to retinal thickness in
this subgroup of participants. Significant positive correla-
tions were identified in the temporal cortex, both with the
global RNFL thickness (r5 .592, P5 .012) and the superiorcontrol groups. PIB groups were not significantly different. Significant dif-
ifferences were found between the PIB1ve group and age-matched control
FL, retinal nerve fiber layer; PIB, Pittsburgh compound [11C].
Fig. 4. Correlations of the PIB1ve and PIB2ve groups RNFL and cortical thickness. Therewere strong positive correlations in the PIB1ve group; however, in
the PIB2ve group, correlations were strongly negative. Abbreviations: DS, Down’s syndrome; NS, not significant; RNFL, retinal nerve fiber layer; PIB, Pitts-
burgh compound [11C].
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other examples of positive correlations across the RNFL
quadrants and cortical regions that were not significant.
Comparisons were also made between the PIB 1ve and
PIB2ve groups, and results showed that as with the full sub-
group, PIB2ve participants had strong positive correlations
between the thickness of the temporal cortex and the global
RNFL (r 5 .684, P 5 .014) and the superior quadrant
(r 5 .604, P 5 .037). In contrast, the PIB 1ve group had
mostly negative associations between cortical and retinal
thicknesses. Correlations were not significant but were strik-
ingly different to those of the PIB2ve group, particularly for
the temporal cortex and global RNFL (r52.612) and supe-
rior quadrant (r 5 2.336). Correlations between temporal
cortex and global RNFL for both PIB groups are shown in
Fig. 4.4. Discussion
People with DS are the most at risk group for developing
AD at a young age, an age similar to that in families with
specific single gene mutations [23]. As with these families,
people with DS are most likely to benefit from the trial of
treatments aimed at preventing the onset and progression
of AD pathology, as the use of such treatments well before
dementia becomes apparent would be justified in this popu-
lation. The challenge for any such trial is to identify an early
biomarker that could be a proxy outcome measure. It is
therefore important to note that the participants with DS
were able to tolerate and cooperate with the OCT assess-
ments. However, the results of this study were not as antici-
pated and further research is needed before the value of
retinal imaging in this older population of people with DS
can be fully determined.
The hypotheses for this study arose from previous
research in the typically developing population at risk of
or with evidence of dementia. In these previous studies, pa-
tients with MCI and AD have shown thinning of the RNFL
with age beyond the rate expected during normal ageing.In people with DS, it was therefore predicted that retinal
structure may reflect these patterns would be emphasized
in a younger age group due to accelerated ageing and high
prevalence of AD and that increased retinal thinning would
be present well before the clinical features of dementia were
apparent.
Contrary to our expectations, we found significantly
thicker RNFL in adults with DS when compared with age-
matched controls and that age-related thinning observed in
the typically developing population was not evident in the
DS group.
Owing to the limited age range of the control group in this
study (18–56 years), we did not anticipate significant age-
related thinning as seen in previous research. This age range
was matched to our DS group and is reflective of the average
life span in DS; therefore, we did except age-related changes
in the DS group. Further investigations into the relationship
between RNFL thickness and age indicated that there was a
nonsignificant increase in thickness in the fourth decade. It is
around the age of 40 that people with DS invariably have ev-
idence of Ab plaques in the brain [24], and this may be the
age that retinal Ab plaques also occur. One study has shown
Ab deposition in the retinas of participants with DS without
dementia. All participants in that study, aged between of 30
and 60 years, had evidence of retinal Ab positivity [25].
Furthermore, three of these participants did not show Ab
positivity in the brain, indicating that retinal Ab may pre-
cede, or be more readily detectable than, cerebral Ab.
Studies in typically developing patients with MCI have
shown increased thickness in the macular region [26,27]
when compared with both age-matched controls and patients
with dementia. Increased RNFL thickness may therefore be
a temporary state linked with early and evolving AD pathol-
ogies. Our data support this theory, as DS participants in
their 50s did not show further increased RNFL thickness
above those in their 40s. However, in this older age group,
there were only a small number of participants. In MCI pa-
tient studies, increased thickness has been attributed to
inflammation caused by gliosis, neuronal death, and M€uller
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toxic peptide Ab42 but may also trigger increased apoptosis
and microglial activity, that both cause cell swelling as a
temporary state.
Correlations between cortical and retinal thicknesses
were as expected in the PIB 2ve group; however, correla-
tions seen in the PIB 1ve group were reversed. Previous
research has shown that people with DS have thicker cortex
than age-matched controls and that cortical thickness is
significantly less in those with DS who are PIB 1ve [28].
The results of this study suggested that the PIB 1ve group
cortical thinning changes exceeded the thinning seen in the
retinal measures.
Retinal changes may be more significant at particular
stages of AD pathology and may be shown as increased
thickness in those at the age when cerebral Ab binding be-
comes apparent. Longitudinal studies assessing change
over time, particularly over the critical time point of the
30–40 seconds, when brain changes become apparent will
be necessary to fully understand retinal structure changes
in DS. A limiting factor of this study is that the PIB 1ve
group consisted of only five participants, age ranging from
42 to 55 years. All participants had confirmed positive Ab
binding between one and four years before retinal imaging;
therefore, we can be reasonably confident of their Ab status
at the time of this study. Studies with larger groups that had
had both retinal and neuroimaging would be needed to vali-
date the findings seen in this study.
In conclusion, retinal and cerebral changes relating to the
development of AD pathology evolve over time and a cross-
sectional study such as this is limited in the conclusions that
can be drawn. The retina is clearly abnormal in people with
DS, but whether this is primarily due to developmental rea-
sons or because of age-related AD pathology remains uncer-
tain. However, our data suggest that RNFL is thicker in the
40s and thinner when cerebral Ab binding becomes apparent.
Taken together with reports of Ab deposition in the retina in
peoplewithDS [25], our findings suggest that the retina is un-
dergoing AD-related changes that later lead to retinal thin-
ning. A longitudinal study combining RNFL and retinal Ab
imaging is required to study such evolving changes and to
determine their potential as a biomarker for AD.Acknowledgements
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1. Systematic review: A literature review using tradi-
tional (e.g. PubMed) sources was undertaken.
Although there were many examples of optical
coherence tomography research in Alzheimer’s dis-
ease (AD), only three studies were identified in peo-
ple with Down’s syndrome (DS). These relevant
citations are appropriately cited.
2. Interpretation: Our hypotheses were based primarily
on research in the AD community, as people with DS
have high prevalence for AD and accelerated ageing.
Our findings indicated that there may be retinal
changes linked to early processes in AD, but that
retinal nerve fiber layer thickness was not correlated
with age in DS.
3. Future directions: This is the first time that the retinal
nerve fiber layer has been measured over a large age
range in peoplewith DS. Furthermore, this is the only
study that has investigated the retinal nerve fiber
layer alongside brain changes and cognition. Further
studies are needed in larger groups, particularly in
those with dementia or early signs of dementia.References
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